首页> 外文期刊>Molecular & cellular proteomics: MCP >Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis
【24h】

Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis

机译:蛋白转录组分析的231 BR乳腺癌细胞:潜在的生物标志物和脑转移治疗目标的鉴定。

获取原文
获取原文并翻译 | 示例
           

摘要

Brain metastases are a devastating consequence of cancer and currently there are no specific biomarkers or therapeutic targets for risk prediction, diagnosis, and treatment. Here the proteome of the brain metastatic breast cancer cell line 231-BR has been compared with that of the parental cell line MDA-MB-231, which is also metastatic but has no organ selectivity. Using SILAC and nanoLC-MS/MS, 1957 proteins were identified in reciprocal labeling experiments and 1584 were quantified in the two cell lines. A total of 152 proteins were confidently determined to be up-or down-regulated by more than twofold in 231-BR. Of note, 112/152 proteins were decreased as compared with only 40/152 that were increased, suggesting that down-regulation of specific proteins is an important part of the mechanism underlying the ability of breast cancer cells to metastasize to the brain. When matched against transcriptomic data, 43% of individual protein changes were associated with corresponding changes in mRNA, indicating that the transcript level is a limited predictor of protein level. In addition, differential miRNA analyses showed that most miRNA changes in 231-BR were up-(36/45) as compared with down-regulations (9/45). Pathway analysis revealed that proteome changes were mostly related to cell signaling and cell cycle, metabolism and extracellular matrix remodeling. The major protein changes in 231-BR were confirmed by parallel reaction monitoring mass spectrometry and consisted in increases (by more than fivefold) in the matrix metalloproteinase-1, ephrin-B1, stomatin, myc target-1, and decreases (by more than 10-fold) in transglutaminase-2, the S100 calcium-binding protein A4, and L-plastin. The clinico-pathological significance of these major proteomic changes to predict the occurrence of brain metastases, and their potential value as therapeutic targets, warrants further investigation.
机译:脑转移瘤是癌症的毁灭性后果,目前尚无用于风险预测,诊断和治疗的特定生物标志物或治疗靶标。在这里,已经将脑转移性乳腺癌细胞系231-BR的蛋白质组与亲代细胞系MDA-MB-231的蛋白质组进行了比较,后者也具有转移性,但没有器官选择性。使用SILAC和nanoLC-MS / MS,在相互标记实验中鉴定出1957种蛋白质,并在这两种细胞系中定量了1584种蛋白质。在231-BR中,共有152种蛋白质被确定上调或下调了两倍以上。值得注意的是,与增加的40/152相比,112/152的蛋白质减少了,这表明特定蛋白质的下调是乳腺癌细胞向大脑转移的基础机制的重要组成部分。当与转录组数据匹配时,43%的单个蛋白质变化与mRNA的相应变化相关,这表明转录水平是蛋白质水平的有限预测因子。此外,差异miRNA分析显示,与下调(9/45)相比,231-BR中的大多数miRNA变化均为上调(36/45)。通路分析表明,蛋白质组的变化主要与细胞信号传导,细胞周期,代谢和细胞外基质重塑有关。 231-BR中的主要蛋白质变化已通过平行反应监测质谱仪确认,并且包括基质金属蛋白酶-1,ephrin-B1,stomatin,myc target-1的增加(超过五倍)和减少(超过转谷氨酰胺酶2,S100钙结合蛋白A4和L-增塑剂的10倍)。这些主要蛋白质组学变化对预测脑转移的发生及其临床价值具有重要的临床病理意义,值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号